Get started
Author

Lorenzo Livi

SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial
2026 · Giulio Francolini, Vanessa Di Cataldo, et al. · The Lancet Oncology · 2
Early outcomes from a phase II randomized trial testing stereotactic body radiation therapy in patients undergoing I line treatment with abiraterone acetate for oligometastatic castration resistant prostate cancer (ARTO trial-NCT03449719)
2023 · G. Francolini, A.G. Allegra, et al. · European Urology · 1
OC-0605 Early outcomes of a randomized trial of SBRT and Abiraterore in mCPRC: ARTO trial NCT03449719
2022 · G. Francolini, B. Detti, et al. · Radiotherapy and Oncology · 1
Ultra-hypofractionated radiotherapy and concomitant oral relugolix for treatment of intermediate risk prostate cancer (ULTRA-HERO).
2026 · Giulio Francolini, Filippo Alongi, et al. · Journal of Clinical Oncology
PDF
ARTO trial (NCT03449719): Long-term overall survival analysis from a randomized phase II trial testing the benefit of stereotactic body radiotherapy addition to abiraterone acetate in oligometastatic castrate resistant prostate cancer patients.
2026 · Giulio Francolini, Saverio Caini, et al. · Journal of Clinical Oncology
PDF
A clinical, evidence-based risk estimator for individualizing benefit and response in oligometastatic prostate cancer (CEREBRO): A tool from the X-Met collaboration.
2026 · Alexander Dean Sherry, Piet Ost, et al. · Journal of Clinical Oncology
PERSIAN trial (NCT03449719): Predictive features of complete biochemical response within a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer.
2026 · Giulio Francolini, Vanessa Di Cataldo, et al. · Journal of Clinical Oncology
A0830 – PERSIAN trial (NCT03449719): A randomized trial testing apalutamide and stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer
2025 · G. Francolini, V. Di Cataldo, et al. · European Urology
A Prospective Observational Trial on Ablative SBRT for Mediastinal and Hilar Lymph nodes: Preliminary Results
2024 · M. Loi, V. Salvestrini, et al. · International Journal of Radiation Oncology*Biology*Physics
PDF
Works count: 9
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type